Clinical Trials Logo

Atrial Arrhythmia clinical trials

View clinical trials related to Atrial Arrhythmia.

Filter by:

NCT ID: NCT02106663 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

Effectiveness Study of Circumferential vs. Segmental Ablation in Paroxysmal Atrial Fibrillation

PAF
Start date: July 2012
Phase: N/A
Study type: Interventional

This is a PI-initiated study that aims to evaluate the efficacy of two different methods of paroxysmal atrial fibrillation (PAF) ablation. There are currently two strategies for PAF ablation that are routinely performed by electrophysiology clinicians: (1) circumferential pulmonary vein ablation (CPVA) and (2) segmental pulmonary vein isolation (SPVI). However, it is not known if one approach is better than the other. This randomized study will evaluate and compare the efficacy of CPVA versus SPVI in subjects undergoing ablation for paroxysmal atrial fibrillation only. Subjects will have a 50/50 chance of receiving either the CPVA or SPVI ablation method.

NCT ID: NCT01439386 Completed - Quality of Life Clinical Trials

Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter

APPROVAL
Start date: September 2011
Phase: Phase 3
Study type: Interventional

This prospective, multi-center, single blinded study aims to compare the influence of two different catheter ablation strategies, on long-term ablation outcome in terms of AF recurrence and quality of life (QoL) in patients presenting with coexistent AF and AFL. The two strategies to be evaluated are 1) the ablation of paroxysmal atrial fibrillation (PAF) with or without flutter (AFL) ablation (AF ± AFL) versus 2) AFL ablation alone.

NCT ID: NCT01188356 Completed - Atrial Arrhythmia Clinical Trials

EMERALD - AssEssment of CoMorbidities & Atrial ArRhythmiA Burden in DuaL-Chamber PaceD Patients

EMERALD
Start date: March 2010
Phase:
Study type: Observational

The purpose of this study is to evaluate the incidence and evolution over-time of co-morbidities in a general dual-chamber pacemaker population (n=2188 patients) through a 2 years follow-up.